Sugi Predict

Sugi Predict / Compounds / SCHEMBL329752

SCHEMBL329752

SCHEMBL329752

O=C(O)c1cc(Cl)cnc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ AKR1C4 P17516 1/20 0.48
▸ AKR1C3 P42330 1/20 0.48
▸ AKR1C2 P52895 1/20 0.48
▸ AKR1C1 Q04828 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.45
▸ TP53 P04637 1/20 0.45
▸ HSD17B10 Q99714 2/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HCAR2 Q8TDS4 1/20 0.44
▸ CYP3A4 P08684 1/20 0.42
▸ DHODH Q02127 2/20 0.42
▸ DYRK1A Q13627 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ LMNA P02545 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ F7 P08709 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28382995 0.82 OPRK1 (0.38) CA1CA2AKR1C4AKR1C3AKR1C2
SCHEMBL915781 0.81 SMN1; SMN2 (0.48) CA1CA2AKR1C4AKR1C3AKR1C2
SCHEMBL29378297 0.81 SMN1; SMN2 (0.48) CA1CA2AKR1C4AKR1C3AKR1C2
Hydrochloric Acid SCHEMBL6988496 0.79 SMN1; SMN2 (0.47) CA1CA2AKR1C4AKR1C3AKR1C2
SCHEMBL9684853 0.79 ALDH1A1 (0.45) CA1CA2AKR1C4AKR1C3AKR1C2
SCHEMBL4701685 0.78 CA12 (0.45) CA1CA2ALDH1A1HSD17B10HPGD
SCHEMBL5989159 0.78 CYP2C8 (0.49) AKR1C3ALDH1A1TP53HSD17B10HPGD
SCHEMBL1989839 0.78 TP53 (0.48) CA1CA2AKR1C4AKR1C3AKR1C2
SCHEMBL20714701 0.78 KDR (0.47) CA1CA2AKR1C4AKR1C3AKR1C2
SCHEMBL30389663 0.78 TP53 (0.48) CA1CA2AKR1C4AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111057095-A Tricyclohexyltin 5-chloro-2-hydroxypyridine-3-formate complex and preparation method and application thereof 衡阳师范学院 2020-04-24 — — CN claimed
US-4960896-A Halogenation with hypohalite salts A. H. ROBINS COMPANY, INC. (US) 1990-10-02 — — US claimed
EP-0225172-A1 Process for the preparation of 5-chloro and 5-bromo-2-hydroxynicotinicacids A.H. ROBINS COMPANY, INCORPORATED (US) 1987-06-10 — — EP claimed
CN-118076589-A Amide compound, preparation method and pharmaceutical application thereof 中国科学院上海药物研究所 2024-05-24 — — CN disclosed
CN-111057095-B Tricyclohexyltin 5-chloro-2-hydroxypyridine-3-formate complex and preparation method and application thereof 衡阳师范学院 2023-07-28 — — CN disclosed
WO-2022268145-A1 AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 中国科学院上海药物研究所 2022-12-29 — — WO disclosed
WO-2022268145-A1 AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 中国科学院上海药物研究所 2022-12-29 — — WO disclosed
CN-115504940-A Amide compound, preparation method and pharmaceutical application thereof 中国科学院上海药物研究所 2022-12-23 — — CN disclosed
CN-111057095-A Tricyclohexyltin 5-chloro-2-hydroxypyridine-3-formate complex and preparation method and application thereof 衡阳师范学院 2020-04-24 — — CN disclosed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 — — EP disclosed
US-9266872-B2 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2016-02-23 — — US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 — — EP disclosed
US-20020111495-A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes PFIZER INC. 2002-08-15 — — US disclosed
EP-1229034-A1 Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes Pfizer Products Inc. (US) 2002-08-07 — — EP disclosed
WO-1995030676-A1 ANTIRHEUMATIC 1-ALKYL-4-HYDROXY-3-(THIEN-3-YL) 1,8-NAPHTHYRIDIN-2(1H)-ONES KNOLL AKTIENGESELLSCHAFT (DE) 1995-11-16 — — WO disclosed
WO-1995007909-A1 ALKYL-1-ALKYL-4-HYDROXY-2-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATES AS ANTI-RHEUMATIC AGENTS KNOLL AG (DE) 1995-03-23 — — WO disclosed
US-5250548-A Treating hypertension, heart failure ABBOTT LABORATORIES (US) 1993-10-05 — — US disclosed
US-4960896-A Halogenation with hypohalite salts A. H. ROBINS COMPANY, INC. (US) 1990-10-02 — — US disclosed
EP-0225172-A1 Process for the preparation of 5-chloro and 5-bromo-2-hydroxynicotinicacids A.H. ROBINS COMPANY, INCORPORATED (US) 1987-06-10 — — EP disclosed
EP-0056144-A1 Carboxylic acid derivatives, their preparation and use as pharmaceuticals Dr. Karl Thomae GmbH (DE) 1982-07-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111495-A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes NOX3, NOX1, NOX4 CA1 3070/4885CA2 434/4885AKR1C4 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.